Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab. - Chen IW; Lin CW; Lin PT; Teng W; Su CW; Wu TH; Hsieh YC; Chen WT; Lin CC; Lin SM; Lin CY (Cancer immunology, immunotherapy : CII, 2026)